Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL

Okcelik, Sezgin; Soydan, Hasan; Ates, Ferhat; Berber, Ufuk; Saygin, Hasan; Sönmez, Güner; Karademir, Kenan.
Int. braz. j. urol ; 42(3): 449-455, tab, graf
Artigo em Inglês | LILACS | ID: lil-785729

Documentos relacionados

  1. Clinical research analysis based on prostate cancer screening diagnosis.
  2. Utilization trend of prebiopsy multiparametric magnetic resonance imaging and its impact on prostate cancer detection: Real-world insights from a high-volume center in southwest China.
  3. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.
  4. Clinical value of minimum apparent diffusion coefficient for prediction of clinically significant prostate cancer in the transition zone.
  5. Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer.
  6. Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies.
  7. Is it necessary for all patients with suspicious lesions undergo systematic biopsy in the era of MRI-TRUS fusion targeted biopsy?
  8. The role of immune PSA complex (iXip) in the prediction of prostate cancer.
  9. [Prospective comparison of cognitive and mpMR/US fusion biopsy for prostate cancer detection].
  10. Is Likert better than PI-RADS at predicting prostate cancer on MRI and can a mathematical algorithm achieve similar results?